Expert Review Implementation Committee (ERIC)

Minutes of the Meeting of 30 June 2017
9.00am, Executive Boardroom

Member participants
Adj Prof John Skerritt (Chair)
Adj Prof Tim Greenaway
Ms Jenny Francis
Ms Adrian Platona
Dr Larry Kelly
Mr David Weiss
Mr Daniel McCabe

Deputy Secretary, Health Products Regulation Group
Chief Medical Adviser
Principal Legal and Policy Adviser
FAS, Medical Devices and Product Quality Division
FAS, Medicines Regulation Division
FAS, Regulatory Practice and Support Division
FAS, Information Technology Division

Apologies
Nil

Attendees
Dr Mark McDonald AS, Regulatory Reforms Branch
Ms Niccie McLay AS, Regulatory Services and Improvement Branch
LF Anthony O'Connor (item 3) AS, Regulatory Knowledge and Technology Services Branch
Dr Rochelle Christian (item 4) AS, Scientific Evaluation Branch
Dr Jane Cook (item 6) AS, Pharmacovigilance and Special Access Branch
Mr Pio Cesarin (item 7) AS, Regulatory Practice, Education & Compliance Branch
Ms Lyndall Soper (items 8 and 9) AS, Complementary & OTC Medicines Branch

1. Minutes of previous meeting

Minutes from the meeting of 16 June 2017 were accepted as an accurate reflection of the meeting.
8. Consultation analysis – Options for the future regulation of ‘low risk’ products

The ERIC was provided with the preliminary analysis of submissions to the public consultation ‘Options for the future regulation of ‘low risk’ products’ and the proposed next steps for this project.

The public consultation paper was published on the TGA website for six weeks (31 March – 12 May). In addition, key stakeholders were also specifically invited to comment. These stakeholders include peak industry bodies and health professional interest groups. A total of 1028 submissions were received, including 65 submissions from organisations. A number of submissions commented on the potential reforms to homoeopathic products.

The ERIC paper included:

- a table of organisations that provided a submission (with key organisations highlighted);
- a tally of responses by option for each ‘low risk’ product type; and
- a summary of key stakeholder submissions.

In many cases the options proposed for the future regulation of ‘low risk’ products were not mutually exclusive and several options could be implemented simultaneously for a particular product type. Despite this, many stakeholders simply indicated support for one option.
ERIC:

- noted the summary of public consultation; and
- noted the next steps for “Options for the future regulation of ‘low risk’ products.”